In the case of epithelial ovarian cancer we act in two stages.»
Francis Rodier, researcher recipient of a Cancer Research Society Operating Grant and his colleague Anne-Marie Mes-Masson, both researchers at the CRCHUM and professors at the Université de Montréal, discovered a way to outsmart ovarian epithelial cancer cells with their “one two punch” approach. Working on cells from ovarian cancer patients, the team discovered that cancer cell enter cellular senesecence phase after a chemotherapy treatment involving PARP inhibitors, an enzyme that causes cancer cells death by keeping them from repairing their DNA and Proliferating.
Dr. Francis Rodier and his team has discovered a therapeutic combination named « one two punch », which forces epithelial ovarian cancer cells to age maturely and keeps them from proliferating, thus causing their death.
“In the case of epithelial ovarian cancer (EOC)—the most common and lethal ovarian cancer—we act in two stages. First, we force the cancer cells to age prematurely i.e., we force them into senescence. This is the first therapeutic punch. We throw our second punch using senolysis, destroying and eliminating them. This strategy requires excellent coordination of the two steps,”
The Cancer Research Society funds highly promising research projects undertaken by Canada’s best scientists. Following a rigorous peer review selection process, about 150 researchers are thus able to advance scientific knowledge to improve cancer prevention, detection and treatments, through various funding programs. These programs are based on scientific excellence, support to new generations of scientists, support to promising underfunded research avenues and partnerships with great impact potential. Since its inception, the Cancer Research Society has thus contributed to major advances in oncology, helping position Canada at the forefront of cancer research in the world.